Globus Medical reported Q2 2026 revenues exceeding expectations, driven primarily by its Enabling Technologies segment alongside steady implant sales. While supply chain constraints related to limited human tissue suppliers pose operational risks, the company’s geographically diverse sales network and product innovation underpin solid growth momentum. Competitive pricing pressures from physician-owned distributorships and healthcare consolidation continue to challenge margin expansion and operating leverage. Key metrics such as sales force coverage and supplier lead times remain critical indicators for near-term performance.